|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] Clinical Data Analyst II ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
STAT/DM |
1³â¡è |
»ó½Ãä¿ë |
06.14 |
|
|
(ÁÖ)¸ÞµåÆÄÅ© |
[¿¬ºÀ4,000¸¸ÀÌ»ó][¼¿ï]±â¼ú»ç¾÷º»ºÎ Ç°Áúº¸Áõ(QA) ÆÀ¿ø±Þ
¼¿ï ¿µµîÆ÷±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
°æ·Â¹«°ü |
ä¿ë½Ã |
12.28 |
|
|
Äܸ޵åÄÚ¸®¾Æ(À¯) |
[¹Ì±¹°è ÀÇ·áÀåºñ] Product Specialist
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
3³â¡è |
ä¿ë½Ã |
06.09 |
|
|
Äܸ޵åÄÚ¸®¾Æ(À¯) |
[¹Ì±¹°è ÀÇ·áÀåºñ] Sales Representative
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
½ÅÀÔ |
ä¿ë½Ã |
06.09 |
|
|
Çູ³ª·¡ ÁÖ½Äȸ»ç |
¿µ¾÷Á÷
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
˂ȍ |
°æ·Â¹«°ü |
ä¿ë½Ã |
06.09 |
|
|
ÁÖ½Äȸ»ç ÀνºÆÃÅͽº |
[Sexual Healthcare EVE] RA ä¿ë(¾à»ç ¿ì´ë)
¼¿ï ÀüÁö¿ª | Çз¹«°ü |
°³¹ß/RA/´ë°ü |
°æ·Â¹«°ü |
ä¿ë½Ã |
06.09 |
|
|
(ÁÖ)Çѱ¹ºñ¿£¾¾ |
Àü·«»ç¾÷º»ºÎ ÇÙ½É Àη ä¿ë
¼¿ï ±¸·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
3³â¡è |
ä¿ë½Ã |
11.03 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] Pharmacovigilance Team ÀÎÅÏ»ç¿ø ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
06.07 |
|
|
(ÁÖ)Á¦À̾¾¹ÙÀÌ¿À |
¹ÙÀÌ¿À °ü·Ã Á¦Ç° ¿µ¾÷(Àåºñ ¹× ½Ã¾à) Á÷¿ø ä¿ë
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
»ý¸í°øÇÐ/¹ÙÀÌ¿À ¿µ¾÷ |
°æ·Â¹«°ü |
ä¿ë½Ã |
04.29 |
|
|
PSI CRO Korea |
[PSI CRO Korea] Feasibility - Site ID Specialist
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
SSU |
2³â¡è |
ä¿ë½Ã |
06.03 |
|
|
¸à¸®ÄÉÇコÄɾîÄÚ¸®¾ÆÁÖ½Äȸ»ç |
¿Ü±¹°è ÀÇ·á±â±â ¿µ¾÷»ç¿ø ¸ðÁý
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
½ÅÀÔ |
ä¿ë½Ã |
09.26 |
|
|
PSI CRO Korea |
[PSI CRO Korea] CRA I/II
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
06.01 |
|
|
PSI CRO Korea |
[PSI CRO Korea] Senior CRA I/II (Lead Monitor Role)
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
06.01 |
|
|
µ§Ã÷ÇöóÀ̽÷γª |
[¿Ü±¹°è ÀÇ·á±â±â] RA/QA Specialist
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
1³â¡è |
ä¿ë½Ã |
05.31 |
|
|
Çѽº¹ÙÀÌ¿À¸Þµå(ÁÖ) |
[Çѽº¹ÙÀÌ¿À¸Þµå ÀÚȸ»ç] ÇѽºÄɾî ÀÇ·á±â±â ¿µ¾÷ ä¿ë
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
°æ·Â¹«°ü |
»ó½Ãä¿ë |
02.23 |
|